BioMarin Pharma (BMRN) Tops Q4 EPS by 12c
Tweet
Share
E-mailGet Alerts BMRN Hot Sheet
Price: $55.54 -1.12%
EPS Growth %: -34.0%
Financial Fact:
Equity in the loss of BioMarin/Genzyme LLC: -104K
Today's EPS Names:
JVA, ARDS, FRHC, More
EPS Growth %: -34.0%
Financial Fact:
Equity in the loss of BioMarin/Genzyme LLC: -104K
Today's EPS Names:
JVA, ARDS, FRHC, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q4 EPS of ($0.47), $0.12 better than the analyst estimate of ($0.59). Revenue for the quarter came in at $230.9 million versus the consensus estimate of $189.01 million.
BioMarin Pharma sees FY2015 revenue of $885-915 million, versus the consensus of $880.6 million.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lennar Corp. (LEN) Misses Q2 EPS by 1c
- Halma Plc. (HLMA:LN) (HLMAF) PT Lowered to GBp50.10 at Goldman Sachs
- KeyBanc Starts Phinia Inc. (PHIN) at Overweight
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
